Head-To-Head Review: Graybug Vision (NASDAQ:GRAY) vs. Mainz Biomed (NASDAQ:MYNZ)

Mainz Biomed (NASDAQ:MYNZ) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Earnings & Valuation

This table compares Mainz Biomed and Graybug Vision”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$917,203.00	6.50	-$26.30 million	($65.60)	-0.05
Graybug Vision	N/A	N/A	-$35.60 million	($24.23)	-0.08

Mainz Biomed has higher revenue and earnings than Graybug Vision. Graybug Vision is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Mainz Biomed has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Institutional & Insider Ownership

49.9% of Graybug Vision shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 7.9% of Graybug Vision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Mainz Biomed and Graybug Vision, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	0	2	1	0	2.33
Graybug Vision	0	0	0	0	0.00

Mainz Biomed presently has a consensus price target of $14.00, suggesting a potential upside of 369.80%. Given Mainz Biomed’s stronger consensus rating and higher possible upside, research analysts clearly believe Mainz Biomed is more favorable than Graybug Vision.

Profitability

This table compares Mainz Biomed and Graybug Vision’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Graybug Vision	N/A	-77.61%	-71.34%

Summary

Mainz Biomed beats Graybug Vision on 9 of the 12 factors compared between the two stocks.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

About Graybug Vision

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.